Mass spectrometry detection of inhaled drug in distal fibrotic lung

HIGHLIGHTS

• who: Theresia A. Mikolasch from the We conducted a prospective clinical study approved by London Camden and Kings Cross Research Ethics Committee and registered on clinicaltrialsgov (NCT03136120) at University College London Hospital (UCLH), London, United Kingdom and sponsored by GlaxoSmithKline. Participants over the age of , with suspected ILD and requiring TBC for further diagnostic assessment, as determined by the ILD multidisciplinary team, were eligible to participate (see Additional file , for full exclusion/inclusion criteria). Most patients had moderately impaired lung function (FVC between , and , percent of predicted). Patients with severe ILD were excluded due to risks of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.